Objective. To evaluated effect of adalimumab treatment on activity of arthritis, enthesitis, psoriasis and functional status in PsA patients (pts). Subjects and methods. 18 pts with active PsA (12 female, 6 male), median age 43,1±10,2 years (yrs) (range 24-56), median duration of psoriasis 16,7±9,6 yrs (range 4-33), median duration of PsA 9,2±6,7 yrs (range 1,5-23) received Adalimumab 40 mg subcutaneously every other week (wk) for 12 wks in open-label study. Evaluations of treatment effects were conducted by the PSARC, ACR 20, 50 and 70, LEI, PASI, BSA, HAQ and CRP at wks 4 and 12. Results. The sings of activity of PsA at baseline were: DAS=4,8 (4,0; 5,45), LEI=4,25 (0,25; 8,05), PASI=10,5 (7,2; 12,1), BSA=1,75 (1; 2), HAQ=1,125 (0,875; 1,5), СRР=27,9 (11,4; 34,6). After 4 wks all parameters significantly improved: DAS=2,85 (2,1; 3,1), LEI=1,86 (0; 3,97), PASI=6,4 (2,8; 8), BSA=0,75 (0,15; 1), HAQ=0,375 (0,125; 0,625), СRP=1,7 (1,4; 3,2) and were maintained after 12 wks: DAS=1,6 (1,3; 2,03), LEI=0,38 (0; 0,89), PASI=1,1 (0,4; 2,2), BSA=0 (0; 0,9), HAQ=0,312 (0; 0,625), СRР=1,75 (0,7; 3,6); p<0,05. 100% pts achieved PSARC at the 4 and 12 wks 55,6; 11,1 and 27,8% PsA pts achieved ACR 20, 50 and 70 at 4 wks and 11,1; 33,3 and 55,6% at 12 wks respectively. Adalimumab was well tolerated throughout the study. Conclusion. Adalimumab therapy significantly reduced the main clinical symptoms of PsA: arthritis, enthesitis, psoriasis. Additionally it improved quality of life PsA patients and was well tolerated.